March 16, 2026
We are pleased to announce the release of our ESG report for 2024/2025, which describes our collective progress across environmental sustainability, social responsibility and ethical governance.
Oxford PharmaGenesis has joined the Sobell Business Club, opening up new opportunities to engage with Oxfordshire’s exceptional Sobell House Hospice and the local community. This follows Oxford PharmaGenesis’s fundraising in partnership with the Rotary Club of Oxford North during our Chairman Graham Shelton’s time as Rotary Club President in 2020–21. Sobell House provides specialist palliative…
Media brand Medical Marketing and Media (MM+M) has listed Oxford PharmaGenesis in the latest Agency 100 – the annual definitive ‘who’s who’ ranking of the sector’s top healthcare marketing firms in North America.
Oxford PharmaGenesis is helping to raise public awareness of the importance of patient diversity in clinical trials through a campaign partnership with the non-profit organization Center for Information and Study on Clinical Research Participation (CISCRP).
Oxford PharmaGenesis continues to boost colleagues’ skills and expertise through a wide range of professional and personal development sessions offered to celebrate Learning at Work Week 2021 (17–23 May).
Monday 10 May to Wednesday 12 May A focus of the 2021 Clinical Data Disclosure, Transparency and Plain Language Summaries virtual conference was on the forthcoming implementation of the EU Clinical Trial Regulation (EU CTR) and the launch of the Clinical Trial Information Service (CTIS). However, the important role of different forms of plain language…
Oxford PharmaGenesis is delighted to have supported the publication of a Delphi consensus manuscript in the Journal of the American Society of Nephrology. The publication highlights the need to increase awareness among key stakeholders of racial health disparities in kidney disease and of APOL1-associated nephropathy.
